Fabry disease Archives -

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102,

Switch data back Chiesi/Protalix long-acting Fabry drug

https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/

The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/

Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

Decision follows approval in Europe

Amicus’ oral Fabry disease drug approved in US

https://pharmaphorum.com/news/amicus-oral-fabry-disease-drug-approved/

England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment for the

Amicus set for share of Fabry market after NICE approval

https://pharmaphorum.com/news/amicus-set-share-fabry-market-nice-approval/

Fabry disease